Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Jan;52(1):65-80.
doi: 10.1310/hpj5201-65.

Lixisenatide

Danial E Baker, Terri L Levien

Lixisenatide

Danial E Baker et al. Hosp Pharm. 2017 Jan.

Abstract

Each month, subscribers to The Formulary Monograph Service receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy/nursing in-services. A comprehensive target drug utilization evaluation/medication use evaluation (DUE/MUE) is also provided each month. With a subscription, the monographs are are available online to subscribers. Monographs can be customized to meet the needs of a facility. Through the cooperation of The Formulary, Hospital Pharmacy publishes selected reviews in this column. For more information about The Formulary Monograph Service, contact Wolters Kluwer customer service at 866-397-3433. The January 2017 monograph topics are bezlotoxumab, buprenorphine buccal, deflazacort, dupilumab, and olaratumab. The DUE is on buprenorphine buccal.

PubMed Disclaimer

Similar articles

  • Bezlotoxumab.
    Baker DE. Baker DE. Hosp Pharm. 2017 Mar;52(3):229-233. doi: 10.1310/hpj5203-229. Hosp Pharm. 2017. PMID: 28439138 Free PMC article.
  • Daclizumab.
    Kim AP, Baker DE. Kim AP, et al. Hosp Pharm. 2016 Dec;51(11):928-939. doi: 10.1310/hpj5111-928. Hosp Pharm. 2016. PMID: 28057953 Free PMC article.
  • Irinotecan Liposome Injection.
    Baker DE, Levien TL. Baker DE, et al. Hosp Pharm. 2017 Feb;52(2):144-150. doi: 10.1310/hpj5202-144. Hosp Pharm. 2017. PMID: 28321142 Free PMC article.
  • Insulin Degludec/Liraglutide.
    Baker DE. Baker DE. Hosp Pharm. 2017 May;52(5):374-380. doi: 10.1177/0018578717715383. Epub 2017 May 1. Hosp Pharm. 2017. PMID: 28804155 Free PMC article. Review.
  • Formulary Drug Review: Belumosudil.
    Levien TL, Baker DE. Levien TL, et al. Hosp Pharm. 2022 Aug;57(4):435-441. doi: 10.1177/00185787211061381. Epub 2021 Dec 7. Hosp Pharm. 2022. PMID: 35898245 Free PMC article. Review.
See all similar articles

Cited by

References

    1. Adlyxin (lixisenatide) [prescribing information]. Bridgewater, NJ: Sanofi-Aventis; July 2016.
    1. Parks MH. NDA approval letter: Adlyxin (lixisenatide NDA 208471). US Food and Drug Administration website. http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2016/208471Orig1.... Published July 27, 2016. Accessed August 1, 2016.
    1. Bolli GB, Munteanu M, Dotsenko S, . et al. Efficacy and safety of lixisenatide once daily vs placebo in people with type 2 diabetes insufficiently controlled on metformin (GetGoal-F1). Diabet Med. 2014; 31( 2): 176– 184. - PubMed
    1. Charbonnel B, Bertolini M, Tinahones FJ, Domingo MP, Davies M.. Lixisenatide plus basal insulin in patients with type 2 diabetes mellitus: A meta-analysis. J Diabetes Complications. 2014; 28( 6): 880– 886. - PubMed
    1. Fonseca VA, Alvarado-Ruiz R, Raccah D, Boka G, Miossec P, Gerich JE.. Efficacy and safety of the once-daily GLP-1 receptor agonist lixisenatide in monotherapy: A randomized, doubleblind, placebo-controlled trial in patients with type 2 diabetes (GetGoal-Mono). Diabetes Care. 2012; 35( 6): 1225– 1231. - PMC - PubMed